1Vinayagamoorthy T, Zhang D, Ye F, Vinayagamoorthy D, Hodkinson R (2017) Can detection of Braf p.V600E mutation be improved? Comparison of allele specific multiplex sequencing to present tests. Journal of Solid Tumors. 7:2.

2Mehnert JM and Kluger HM (2012) Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies. Curr Oncol Rep. 14: 449–457.

3Mellert H, Foreman T, Jackson L, et al. (2017) Development and Clinical Utility of a Blood- Based Test Service for the Rapid Identification of Actionable Mutations in Non–Small Cell Lung Carcinoma. 19: 3 404–416.

4Yoruker EE, Holdenrieder S, Gezer U (2016) Blood-based biomarkers for diagnosis, prognosisand treatment of colorectal cancer. Clinica Chimica Acta. 455: 1 26-32.

5Moorthy T (2018) Targeted therapy: a potential oversight in trial protocol. The Lancet Oncology. 19: 39.

6Prieto-Potin I, Montagut C, Bellosillo B, et al. (2018) Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. J Mol Diagn. 20 :664-676.

7Kevin Q, Qiulu P, Xi Z, et al. (2013) Detection of BRAF V600 Mutations in Metastatic Melanoma. Comparison of the Cobas 4800 and Sanger Sequencing Assays. The Journal of Molecular Diagnostics. 15: 790.

8Moorthy T (2018) An algorithm to evaluate the efficacy of detecting somatic mutations. Journal of Solid Tumors 8: 2.